Survodutide (6mg)

What is Survodutide?

Survodutide (BI 456906) is a synthetic, acylated peptide that acts as a dual agonist at the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R). Designed for once-weekly research administration, it combines mechanisms that reduce food intake with increased energy expenditure via enhanced fat oxidation. Preclinical and early clinical data indicate significant metabolic effects, including reduced body weight, improved glucose tolerance, and increased FGF21 expression in model systems.

Chemical Structure of Survodutide

Survodutide is a 29–amino-acid peptide acylated with an 18‑carbon fatty acid (C18) to prolong systemic exposure through reversible albumin binding. Its structure includes deletion of DPP‑4 cleavage sites for extended activity. PubChem lists its molecular formula as C₁₉₂H₂₈₉N₄₇O₆₁, with a monoisotopic mass of approximately 4,229 Da. Cryo-EM studies confirm the C18 acyl tail and structural adaptations aligned to GCGR and GLP‑1R binding.

What Are the Effects of Survodutide?

• Appetite Suppression & Weight Loss: Clinical phase II studies in obese populations reported up to ~19% body weight reduction over 46 weeks following weekly dosing.
• Enhanced Energy Expenditure: Animal and human data demonstrated increased fat oxidation and FGF21 expression, indicating activation of metabolic thermogenesis pathways.
• Improved Glycemic Control: In type 2 diabetic models, Survodutide decreased HbA1c by up to 1.7% at 16 weeks.
• Metabolic Biomarker Modulation: Studies reveal enhanced insulin sensitivity and β-cell function, with reductions in glucagon levels.
• Pharmacokinetic Durability: The C18 modification extends half-life to ~44 hours in rodents and ~140 hours in canines, supporting weekly dosing with stable receptor engagement.

Citations

1. Pep-Pedia – Survodutide (BI 456906): acylated dual GCGR/GLP‑1R agonist, 29 AA peptide used in metabolic studies. Survodutide – Dual Receptor Mechanism
2. le Roux CW, et al. “Glucagon and GLP‑1 receptor dual agonist survodutide for obesity: a randomised, double‑blind, placebo‑controlled, dose‑finding phase 2 trial.” Lancet Diabetes Endocrinol. 2024;12(3):162–173. PMID: 38330987. Survodutide – Dual Receptor Mechanism
3. Cardiometabolic Health Center post-hoc analysis: Survodutide improves insulin sensitivity and glucagon biomarkers in T2D/overweight subjects. 2024. Survodutide – Dual Receptor Mechanism
4. ChemicalBook summary – Survodutide pharmacokinetics; molecular formula C₁₉₂H₂₈₉N₄₇O₆₁; mass ~4229 Da; dosing effects in DIO mice and dogs. Survodutide – Dual Receptor Mechanism
5. Diabetes Journals: Molecular basis of Survodutide—cryo-EM structures and receptor engagement studies. 2025. Survodutide – Dual Receptor Mechanism
6. IUPHAR/BPS Guide to PHARMACOLOGY – Survodutide ligand profile: C18 acylation and dual receptor activity. Survodutide – Dual Receptor Mechanism
7. European Heart Journal Supplement: Phase II weight loss results (mean 18.7–19% at 46 weeks). 2024. Survodutide – Dual Receptor Mechanism